Cost-Effectiveness of Ranibizumab for Eye Disease
Author Information
Author(s): Susan F. Hurley, Jane P. Matthews, Robyn H. Guymer
Primary Institution: Bainbridge Consultants
Hypothesis
Is ranibizumab cost-effective for treating neovascular age-related macular degeneration over a 10-year period?
Conclusion
Ranibizumab was cost-saving from a societal perspective and cost-effective when priced below $1000 per dose.
Supporting Evidence
- Ranibizumab reduced the probability of blindness from 56% to 34% over 10 years.
- The cost per QALY gained varied significantly based on the price of ranibizumab.
- Including caregiver costs made ranibizumab treatment cost-saving under all price assumptions.
Takeaway
This study looked at how much it costs to use a medicine called ranibizumab to help people with a serious eye problem. It found that if the medicine is cheap enough, it saves money and helps people see better.
Methodology
A Markov model was used to simulate disease progression and estimate costs and outcomes over 10 years.
Limitations
The model's assumptions about long-term efficacy and dosing regimens were based on limited trial data.
Participant Demographics
The analysis focused on a hypothetical 67-year-old woman with neovascular age-related macular degeneration.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website